Provided by Tiger Trade Technology Pte. Ltd.

Alaunos Therapeutics

0.8875
-0.0730-7.60%
Post-market: 0.8601-0.0274-3.09%19:16 EDT
Volume:125.54K
Turnover:112.77K
Market Cap:2.25M
PE:-0.50
High:0.9999
Open:0.9521
Low:0.8529
Close:0.9605
52wk High:4.59
52wk Low:0.8529
Shares:2.54M
Float Shares:2.06M
Volume Ratio:0.93
T/O Rate:6.11%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7684
EPS(LYR):-2.1977
ROE:-185.95%
ROA:-81.13%
PB:3.46
PE(LYR):-0.40

Loading ...

Alaunos Therapeutics Announces New Registered Direct Offering

TIPRANKS
·
Sep 23

Alaunos Therapeutics Prices Registered Direct Offering at USD 1.46 Per Share for USD 1.12 Million Gross Proceeds

Reuters
·
Sep 18

Alaunos Therapeutics, Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under NASDAQ Rules

THOMSON REUTERS
·
Sep 18

Alaunos Therapeutics Cuts Stockholder Meeting Quorum Requirement to One-Third from Majority

Reuters
·
Sep 17

Alaunos Net Loss Narrows to $1.9 Million in Q2 2026; Revenue Posts no Revenue in H1 2026

Reuters
·
Aug 15

Alaunos Reports New Preclinical Analysis Showing Aln1003 Lowers Liver Weight in 48-day DIO Mouse Study

Reuters
·
Jun 29

Alaunos Therapeutics reports metabolic improvements with ALN1003 in studies

TIPRANKS
·
May 27

Alaunos publishes investor presentation on ALN1003 preclinical data

Reuters
·
May 26

Alaunos Therapeutics reports updated preclinical data from ALN1003 mouse studies

TIPRANKS
·
May 18

Alaunos reports preclinical ALN1003 data in obesity mouse studies showing improved insulin markers

Reuters
·
May 18

Alaunos Therapeutics Inc - Aln1003-Treated Animals Had Significantly Lower Homa-Ir Scores After Body Fat Adjustment

THOMSON REUTERS
·
May 18

Alaunos Reports Preclinical Aln1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models

THOMSON REUTERS
·
May 18

Alaunos Therapeutics Inc - Cash Runway Extends Into Q2 2026

THOMSON REUTERS
·
May 18

Alaunos net loss widens to $1 million in Q1 FY26

Reuters
·
May 16

Valion Bio appoints Melinda Lackey general counsel, SVP legal affairs

Reuters
·
May 05

Press Release: Valion Bio Appoints Melinda Lackey as General Counsel

Dow Jones
·
May 05

Alaunos Therapeutics Faces Nasdaq Non-Compliance, Delisting Risk

TIPRANKS
·
Apr 16

Alaunos Therapeutics flags Nasdaq noncompliance after stockholders’ equity falls below 2,500,000

Reuters
·
Apr 16

Alaunos FY25 net loss narrows 10.8% to $4.2 million

Reuters
·
Apr 01